Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03302754 · ClinicalTrials.gov registry record · NA
Precision Dosing of Alemtuzumab
A NA study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT03302754 is a NA study that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 12 participants.
The verdict
NCT03302754, a NA study, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to conduct a pilot trial of a Precision Dosing approach to alemtuzumab dosing for allogeneic hematopoietic cell transplantation of patients with non-malignant diseases. The investigators will measure the ability to use a population PK model of alemtuzumab to target patient Day 0 alemtuzumab levels to 0.15-0.6ug/mL in a pilot study of 20 patients.
Interventions
- DRUG Alemtuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-10-05 |
| Est. Completion | 2019-03-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03302754
The ClinicalTrials.gov registry entry for NCT03302754 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alemtuzumab is the first listed.
NCT03302754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03302754 about?
NCT03302754 is a clinical study titled "Precision Dosing of Alemtuzumab". The purpose of this study is to conduct a pilot trial of a Precision Dosing approach to alemtuzumab dosing for allogeneic hematopoietic cell transplantation of patients with non-malignant diseases. The investigators will measure the ability to use a population PK model of alemtuzumab to target patie...
What is the current status of trial NCT03302754?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2017-10-05. Estimated completion is 2019-03-10.
What interventions are being tested in trial NCT03302754?
The interventions under investigation include: Alemtuzumab (DRUG).
Who is sponsoring clinical trial NCT03302754?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.